menu
    • menu

    Company profile for Atara Biotherapeutics

    NEW Drugs in Dev: 8
    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Atara Biotherapeutics (Nasdaq:ATRA) is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. The company was founded in 2012 and named after Atara Ciechanover who suffered from cancer before passing away.Originating from over a decade of groundbreaking clinical experience at Memorial Sloan Kettering and QIMR Berghofer, Atara’s off...
    Atara Biotherapeutics (Nasdaq:ATRA) is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. The company was founded in 2012 and named after Atara Ciechanover who suffered from cancer before passing away.Originating from over a decade of groundbreaking clinical experience at Memorial Sloan Kettering and QIMR Berghofer, Atara’s off-the-shelf, allogeneic T cells are bioengineered from donors with healthy immune function and allow for rapid delivery from inventory to patients without a requirement for pretreatment.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Atara BiotherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    611 Gateway Blvd, Suite 900 South San Francisco, CA 94080
    Telephone
    Telephone
    (650) 278-8930
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.atarabio.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/atarabio
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/atarabio?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Atara Bio Reports Q1 2026 Financials And Operational Advancements
    Atara Bio Reports Q1 2026 Financials And Operational Advancements

    12 May 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7423999

    FIRSTWORD PHARMA
    12 May 2026
    Share Share
    Atara, Pierre's Cell Therapy to Get Another Shot at FDA Approval
    Atara, Pierre's Cell Therapy to Get Another Shot at FDA Approval

    09 May 2026

    // BIOSPACE

    https://www.biospace.com/fda/fda-reverses-course-on-atara-pierre-fabres-twice-rejected-cell-therapy-after-prasads-exit

    BIOSPACE
    09 May 2026
    Share Share
    Atara Bio Announces Q4 and Full Year 2025 Financial Results
    Atara Bio Announces Q4 and Full Year 2025 Financial Results

    16 Mar 2026

    // BUSSINESSWIRE

    https://www.businesswire.com/news/home/20260316154875/en/Atara-Biotherapeutics-Announces-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Operational-Progress

    BUSSINESSWIRE
    16 Mar 2026
    Share Share
    Atara Biotherapeutics Provides Regulatory Update On Tabelecleucel
    Atara Biotherapeutics Provides Regulatory Update On Tabelecleucel

    03 Mar 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260303134105/en/Atara-Biotherapeutics-Provides-Regulatory-Update-on-Tabelecleucel

    BUSINESSWIRE
    03 Mar 2026
    Share Share
    Atara Rises On FDA Inconsistency Causing Cell Therapy Rejection
    Atara Rises On FDA Inconsistency Causing Cell Therapy Rejection

    26 Feb 2026

    // BIOSPACE

    https://www.biospace.com/fda/atara-climbs-amid-report-of-fda-inconsistency-leading-to-cell-therapys-rejection

    BIOSPACE
    26 Feb 2026
    Share Share
    Atara Biotherapeutics Provides A Business Update
    Atara Biotherapeutics Provides A Business Update

    23 Feb 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-02-23/atara-biotherapeutics-provides-a-business-update

    PHARMIWEB
    23 Feb 2026
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search